Synthesis and Characterization of Chiral Impurities of Mirabegron, Used as an Overactive Bladder Drug

Abstract

Mirabegron is used to treat overactive bladder that drug substance is the first β3-adrenoreceptor (AR) agonist. The mechanism of action of Mirabegron is as an adrenergic beta-3-Agonist and cytochrome P450 3A inhibitor, and p-Glycoprotein inhibitor. This molecule is optical active and having one chiral center and only (R)-Mirabegron presents pharmacological activity being (S)-Mirabegron an impurity which critical to control. During the process development of Mirabegron, the chiral impurity of drug substance is challenging and also challenging to all pharmaceutical industries too, the opposite isomeric impurity is introduced form its key starting material and it follows the same reaction mechanism path up to final drug substance, present work describe the synthesis of chiral impurities of each intermediate, including key starting material and its  drug substance and their characterization by spectral data (MS,1H-NMR and 13C-NMR). This work will help quality control (QC) to identify and control these impurities in the Mirabegron drug substance as per ICH guideline.